Oncotelic Therapeutics Implements PDAOAI Platform
Oncotelic Therapeutics (OTCQB:OTLC) has announced the implementation of its AI platform PDAOAI, designed for document search and analysis in knowledge-based industries. The platform, accessible via PDAO tokens, uses advanced semantic filtering and LLM-based contextual answering to enable precise queries across large document sets.
The system has already demonstrated success at Sapu Bioscience, a subsidiary of GMP Biotechnology (where Oncotelic holds 45% ownership), helping achieve GMP compliance within one year through efficient staff training and SOP implementation. The platform will be governed through Pet2DAO using PDAO tokens, ensuring transparent, community-driven governance.
Oncotelic Therapeutics (OTCQB:OTLC) ha annunciato l'implementazione della sua piattaforma AI PDAOAI, progettata per la ricerca e l'analisi di documenti nei settori basati sulla conoscenza. La piattaforma, accessibile tramite i token PDAO, utilizza filtri semantici avanzati e risposte contestuali basate su LLM per consentire query precise su ampi set di documenti.
Il sistema ha già dimostrato successo presso Sapu Bioscience, una sussidiaria di GMP Biotechnology (dove Oncotelic detiene il 45% delle azioni), contribuendo a raggiungere la conformità GMP entro un anno attraverso un'efficiente formazione del personale e l'implementazione di SOP. La piattaforma sarà governata tramite Pet2DAO utilizzando i token PDAO, garantendo una governance trasparente e guidata dalla comunità.
Oncotelic Therapeutics (OTCQB:OTLC) ha anunciado la implementación de su plataforma de IA PDAOAI, diseñada para la búsqueda y análisis de documentos en industrias basadas en el conocimiento. La plataforma, accesible a través de tokens PDAO, utiliza filtrado semántico avanzado y respuestas contextuales basadas en LLM para permitir consultas precisas a través de grandes conjuntos de documentos.
El sistema ya ha demostrado éxito en Sapu Bioscience, una subsidiaria de GMP Biotechnology (donde Oncotelic posee el 45% de las acciones), ayudando a lograr el cumplimiento de GMP en un año a través de una formación eficiente del personal y la implementación de SOP. La plataforma será gobernada a través de Pet2DAO utilizando tokens PDAO, asegurando una gobernanza transparente y impulsada por la comunidad.
Oncotelic Therapeutics (OTCQB:OTLC)는 지식 기반 산업에서 문서 검색 및 분석을 위해 설계된 AI 플랫폼 PDAOAI의 구현을 발표했습니다. PDAO 토큰을 통해 접근 가능한 이 플랫폼은 고급 의미 필터링과 LLM 기반의 맥락적 응답을 사용하여 대량의 문서 세트에 대한 정확한 쿼리를 가능하게 합니다.
이 시스템은 GMP Biotechnology의 자회사인 Sapu Bioscience에서 이미 성공을 거두었으며(여기서 Oncotelic은 45%의 지분을 보유), 효율적인 직원 교육과 SOP 구현을 통해 1년 이내에 GMP 준수를 달성하는 데 기여했습니다. 이 플랫폼은 PDAO 토큰을 사용하여 Pet2DAO를 통해 관리되어 커뮤니티 주도의 투명한 거버넌스를 보장합니다.
Oncotelic Therapeutics (OTCQB:OTLC) a annoncé la mise en œuvre de sa plateforme d'IA PDAOAI, conçue pour la recherche et l'analyse de documents dans les industries basées sur la connaissance. La plateforme, accessible via des jetons PDAO, utilise un filtrage sémantique avancé et des réponses contextuelles basées sur LLM pour permettre des requêtes précises sur de grands ensembles de documents.
Le système a déjà montré son succès chez Sapu Bioscience, une filiale de GMP Biotechnology (où Oncotelic détient 45% des parts), contribuant à atteindre la conformité GMP en un an grâce à une formation efficace du personnel et à la mise en œuvre de SOP. La plateforme sera gouvernée par Pet2DAO en utilisant les jetons PDAO, garantissant une gouvernance transparente et dirigée par la communauté.
Oncotelic Therapeutics (OTCQB:OTLC) hat die Implementierung seiner KI-Plattform PDAOAI bekannt gegeben, die für die Dokumentensuche und -analyse in wissensbasierten Branchen konzipiert ist. Die Plattform, die über PDAO-Token zugänglich ist, verwendet fortschrittliche semantische Filterung und LLM-basierte kontextuelle Antworten, um präzise Abfragen über große Dokumentensätze zu ermöglichen.
Das System hat bereits bei Sapu Bioscience, einer Tochtergesellschaft von GMP Biotechnology (an der Oncotelic 45% der Anteile hält), Erfolge gezeigt und dazu beigetragen, innerhalb eines Jahres GMP-Compliance durch effiziente Schulungen des Personals und die Umsetzung von SOPs zu erreichen. Die Plattform wird über Pet2DAO mittels PDAO-Token gesteuert, um eine transparente, gemeinschaftsbasierte Governance sicherzustellen.
- Successfully implemented AI platform in Sapu Bioscience, achieving GMP compliance in one year
- 45% ownership stake in GMP Biotechnology's subsidiary Sapu Bioscience
- Patent-pending technology for document analysis and search
- None.
AGOURA HILLS, Calif., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), today announced the implementation of its artificial intelligence (AI) platform PDAOAI. The platform is designed to streamline document search and analysis, to address the growing needs of knowledge-based industries including pharmaceutical and biotechnology. We have been enhancing the capabilities of the platform over the past one year. The platform will be accessible via PDAO tokens, which the Company initially released to eligible shareholders in 2023.
This search platform transforms how users navigate large document sets by enabling precise, parallel queries across structured datasets. It leverages advanced semantic filtering and large language model (LLM)-based contextual answering, built on patent-pending technology. Traditional AI chatbots often rely on broad, global search methods, which can lead to issues like dilution and bias. In contrast, this platform queries individual documents to deliver crisp, precise answers drawn from vast collections, including tens of thousands of scientific articles or enterprise-level knowledge bases. This method is intended to scale to support infinite documents, delivering precision-driven, fine-grained responses.
PDAOAI is designed for enterprise users and scientists, currently with a particular emphasis on the biotechnology industry. Sapu Bioscience, LLC, a wholly owned subsidiary of GMP Biotechnology, Limited, in which we are a
The platform will be governed through our decentralized autonomous organization (DAO), Pet2DAO, using the PDAO token. This decentralized structure ensures transparent decision-making, community-driven governance, and eliminates reliance on centralized authorities for managing platform resources.
“This is just one of many solutions we have planned for PDAOAI. We are excited to see the successful implementation of PDAOAI at SAPU’s GMP facility. This rapid onboarding into GMP is just the beginning”, said Scott Myers, Product Manager, Oncotelic.
"This combination of semantic filtering and contextual question-answering, applied at the document level, has proved to be a game-changer in our approach to document searching, analysis and summarization, " said Mike Potts, VP of Data Science, Oncotelic.
“PDAOAI is already driving value for Sapu Biosciences, enabling advancements beyond GMP compliance and accelerating drug development. We look forward to introducing new capabilities as they become available,” said Saran Saund, Chief Business Officer, Oncotelic. “Looking ahead, we plan to expand the platform’s applications beyond life sciences, with a particular focus on semiconductors, where it has the potential to drive significant innovation.”
Interested users can inquire further by emailing ir@oncotelic.com.
About Pet2DAO/PDAO
Pet2DAO, our DAO Company was established in late 2022 and launched its token, PDAO, in early 2023. PDAO was launched as a utility token, integrating traditional corporate governance with innovative DAO architecture powered by AI and blockchain technologies.
About Oncotelic
Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2DAO, the actual filing of a registration statement and approval of the PDAO, or any other tokens that we may launch, as registrable securities with the SEC through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable.. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 12, 2024 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise.
Contact Information:
For Oncotelic Therapeutics, Inc.:
Investor Relations
ir@oncotelic.com
FAQ
What is Oncotelic's (OTLC) new PDAOAI platform and how does it work?
How has PDAOAI benefited Sapu Bioscience's GMP compliance process?
How can investors access Oncotelic's (OTLC) PDAOAI platform?
What is the governance structure for Oncotelic's (OTLC) PDAOAI platform?
